Phytochemistry and pharmacognosy.

During the past 50 years there have been tremendous advances in chemical and biological techniques of analysis that have transformed research in pharmacognosy. The PSE has regularly held symposia of relevance to pharmacognosy and some of these are briefly reviewed in the area of natural products from higher plants. These symposia have charted the developments that link pharmacognosy with phytochemistry and illustrate the application of increasingly more sophisticated analytical techniques to the discovery of biologically active compounds. Plants have yielded clinical drugs, either as natural product molecules, or as synthetic modifications, particularly for chemotherapeutic treatment of cancer and malaria. Aspects of biotechnology, traditional medicines and herbal medicinal products are briefly discussed.

Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties.

This paper reviews the chemistry, pharmacology and clinical properties of Echinacea species used medicinally. The Echinacea species Echinacea angustifolia, Echinacea pallida and Echinacea purpurea have a long history of medicinal use for a variety of conditions, particularly infections, and today echinacea products are among the best-selling herbal preparations in several developed countries. Modern interest in echinacea is focused on its immunomodulatory effects, particularly in the prevention and treatment of upper respiratory tract infections. The chemistry of Echinacea species is well documented, and several groups of constituents, including alkamides and caffeic acid derivatives, are considered important for activity. There are, however, differences in the constituent profile of the three species. Commercial echinacea samples and marketed echinacea products may contain one or more of the three species, and analysis of samples of raw material and products has shown that some do not meet recognized standards for pharmaceutical quality. Evidence from preclinical studies supports some of the traditional and modern uses for echinacea, particularly the reputed immunostimulant (or immunomodulatory) properties. Several, but not all, clinical trials of echinacea preparations have reported effects superior to those of placebo in the prevention and treatment of upper respiratory tract infections. However, evidence of efficacy is not definitive as studies have included different patient groups and tested various different preparations and dosage regimens of echinacea. On the basis of the available limited safety data, echinacea appears to be well tolerated. However, further investigation and surveillance are required to establish the safety profiles of different echinacea preparations. Safety issues include the possibility of allergic reactions, the use of echinacea by patients with autoimmune diseases and the potential for echinacea preparations to interact with conventional medicines.

Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.

The naturally occurring bitter principle quassin (1) was converted chemically into the gamma-lactone quassilactone (13) in an attempt to enhance its antiplasmodial activity. The in vitro antiplasmodial activity of 13 against Plasmodium falciparum (K1) (IC(50) = 23 microM) was 40-fold greater than that of 1. However, one of the intermediates, compound 8, the 15beta-hydroxy,16-O-m-chlorobenzoyl analogue of 1, was 506-fold more active than 1 against P. falciparum (IC(50) = 1.8 microM) and only 3-fold less potent than chloroquine. In addition, 8 displayed the best cytotoxic/antiplasmodial ratio (112) of all of the compounds tested. In the course of this work a dimer, neoquassin ether (6), linked at C-16 was also prepared; 6 was found to have weak antiplasmodial activity (IC(50) = 9.7 microM).

50 years of medicinal plant research - every progress in methodology is a progress in science.

Many scientific methods of analysis have been developed for the investigation of the constituents and biological activities of medicinal plants during the 50 years since the inaugural meeting of the Gesellschaft für Arzneipflanzenforschung (GA). The chromatographic (e. g., TLC, GLC, HPLC), spectroscopic (e. g., UV, IR, 1H- and 13C-NMR, MS), and biological (e. g., anticancer, anti-inflammatory, immunostimulant, antiprotozoal, CNS) techniques utilized for medicinal plant research are briefly reviewed. The contribution that advances in scientific methodology have made to our understanding of the actions of some herbal medicines (e. g., Echinacea, Ginkgo, St John's wort, Cannabis), as well as to ethnopharmacology and biotechnology, are briefly summarized. Plants have provided many medicinal drugs in the past and remain as a potential source of novel therapeutic agents. Despite all of the powerful analytical techniques available, the majority of plant species has not been investigated chemically or biologically in any great detail and even well known medicinal plants require further clinical study.

Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes.

Four new terpenoids, comprising three nor-secofriedelanes (1-3) and one nor-friedelane (4), were isolated from Galphimia glauca, together with the known flavonol quercetin and the sterols stigmasterol and sitosterol 3-O-beta-D-glucoside. The structure elucidation of the new isolates was conducted by 1D and 2D NMR techniques. Compounds 1-4 were given the trivial names galphin A, galphin B, galphin C, and galphimidin, respectively. All isolates were tested for in vitro antiprotozoal and cytotoxic activities. Quercetin was the only substance isolated that showed any antiprotozoal activity, and this was weak; the IC(50) values were 14 microM against Plasmodium falciparum K1, 13.2 microM against Trypanosoma brucei brucei, and 63.8 microM against Leishmania donovani. Quercetin was found to be inactive against KB cells (IC(50) = 295.8 microM).

In vitro activity of Triclisia patens and some bisbenzylisoquinoline alkaloids against Leishmania donovani and Trypanosoma brucei brucei.

In the search for antiprotozoal compounds from natural sources, Triclisia patens displayed activity against L. donovani promastigotes (IC(50) = 1.5 microg/mL) and T. b. brucei blood stream trypomastigote forms (IC(50) = 31.25 microg/mL). In addition, a total of 20 bisbenzylisoquinoline alkaloids were screened for antileishmanial and antitrypanosomal activity in vitro. Fangchinoline (IC(50) = 0.39 microM) was found to be as active as the standard pentamidine against Leishmania donovani promastigotes. Phaeanthine was three-fold more active (IC(50) = 2.41 microM; 1.5 microg/mL) than the standard drug Pentostam against L. donovani amastigotes, but at this concentration was toxic to murine macrophages. In contrast, cocsoline (IC(50) = 12.3 microM; 6.76 microg/mL) was as active as Pentostam, and was not toxic to macrophages at this concentration. Thalisopidine showed the strongest activity (IC(50) = 1.14 microM) against Trypanosoma brucei brucei blood stream form trypomastigotes, but was less active than pentamidine.